The contribution of disseminated fibrin clot formation to the pathogenesis of canine endotoxin shock was explored in control dogs and in those defibrinated with a purified fraction of Malayan pit viper venom. The hemodynamic and humoral responses after the administration of an intravenous challenge dose of Escherichia coli endotoxin were comparable as was mortality. It is concluded that, although the role of the coagulation sequence in canine endotoxin shock is unclear, it does not appear to be determinative.
The contribution of disseminated fibrin clot formation to the pathogenesis of canine endotoxin shock was explored in control dogs and in those defibrinated with a purified fraction of Malayan pit viper venom. The hemodynamic and humoral responses after the administration of an intravenous challenge dose of Escherichia coli endotoxin were comparable as was mortality. It is concluded that, although the role of the coagulation sequence in canine endotoxin shock is unclear, it does not appear to be determinative.
Bacterial endotoxins activate many humoral pathways in vivo, including complement (8, 11) , kinin (24) , and coagulation (9) sequences. Although some of the consequences of kinin (24) and complement (8) activation in canine endotoxin shock have been described recently, the importance of disseminated intravascular coagulation in this situation is unclear.
Anticoagulant pretreatment of dogs has in some instances markedly increased survival after endotoxin challenge (9, 14) and in others had no effect on mortality (22, 25) . Because heparin, the anticoagulant used in most such studies, may have effects other than those on coagulation system components (7, 19) , the variable results may be independent of the anticoagulant properties of heparin. Therefore, the effects of endotoxin were studied in dogs with prior defibrination induced by a purified fraction of Malayan pit viper (MPV) venom, an agent known to act only upon the terminal effector portion of the coagulation system t1).
(A preliminary report of these studies was published previously: Circulation 42(Suppl. (23) , and fibrinogen levels (13) . Blood leukocyte and platelet counts (23) were also obtained in several experiments.
In seven control experiments, after a 60-min period during which base line measurements were obtained, an approximately 80% lethal dose of purified Escherichia coli endotoxin (0.75 mg/kg) (17) was injected intravenously as a bolus, and pressure measurements and blood samples were obtained over a 4-h period. In six other animals a chromatographically purified fraction of MPV venom (2) was infused over a 60-min period (0.39 to 0.78 mg/dog). Over the next several hours clotting times were frequently determined until the blood became incoagulable. Endotoxin was then administered as described above, and the animals were monitored for an additional 4 h.
RESULTS
MPV venom is a potent defibrinating agent (Table 1) . Three hours after the start of the infusion, the blood was incoagulable in glass, as demonstrated by the Lee-White clotting times. The plasma fibrinogen was markedly reduced to approximately 10% of control levels. These changes were highly significant (P < 0.005; Student's t test). The MPV venom infusion caused no discernible hemodynamic changes, as has been reported previously (15) . Figure 1 demonstrates the hemodynamic changes after endotoxin injection in the control and defibrinated animals. There was no real difference between the two groups with respect to the mean arterial blood pressure response in either the immediate postchallenge period or the later periods (except for several intermediate time intervals where there were slight statistically significant differences). The especially close hemodynamic correspondence of the control and experimental groups during the first hour after challenge is seen in Fig. 2 Table 2 shows the changes in plasma complement after the various experimental interventions. It is seen that endotoxin caused a significant early decrease in complement levels in both control and defibrinated animals (P < 0.05; Student's t test) but that MPV venom treatment alone caused no significant drop in complement. Figure 3 shows the response of the leukocyte and platelet counts after MPV venom and then endotoxin challenge in two experiments. Neither was remarkably altered by MPV venom alone, but endotoxin caused a rapid and marked decline of both. This response is identical to that reported previously in endotoxinchallenged animals (27) . We have also seen this response in all control animals so studied (not ,shown). The mortality in both groups of animals was similar, with all animals in the control DISCUSSION Endotoxin may interact with the coagulation sequence in at least two ways: (i) through direct activation of Hageman factor (21) or possibly indirectly through the induction of endothelial damage (10) , and (ii) by causing platelet aggregation and release (5) in the presence of a heat-labile serum factor (26) , which may (12) or may not (4) be complement. Hence, endotoxin interaction with coagulation system components can potentially alter homeostasis through the generation of kinins resulting from Hageman factor activation, through the release of serotonin (3) or other vasoactive substances (26) from platelets, through the formation of platelet plugs (G. Evans and J. F. Mustard, J. Clin. Invest. 47:31a, 1968), or as a result of disseminated fibrin clot formation (14) .
In contrast to heparin, the anticoagulant action of which stems from the ability of that agent to inhibit the formation and action of thrombin (presumably by electrostatically binding to the relevant clotting factors) (6), MPV venom induces the conversion of fibrinogen to an unstable form of fibrin without altering other coagulation factors or platelet number or function. Degradation of MPV venom-formed fibrin is presumably achieved by the fibrinolytic and reticuoendothelial systems These findings are not in conflict with previous data; rather, they may clarify some of the apparently contradictory findings of the past. The variable response to heparin anticoagulation (9, 14, 22, 25) may be dose related and dependent upon properties of heparin other than its ability to prevent the formation of fibrin. For example, it has been suggested that heparin may activate the reticuloendothelial system and that this may be important in the defense reaction against endotoxin (7) . Large doses of heparin can also inhibit antigen-antibody reaction-induced aggregation of platelets (19) , and it is possible they may interfere with endotoxin-induced aggregation. There is also no conflict with the suggestion that Hageman factor activation or platelet activation and dissolution may be an important feature of the endotoxin response, since it has been shown that MPV venom does not alter early clotting factors (1), and our data show that MPV venom does not alter the usual platelet or leukocyte response to endotoxin (27) . It is also of interest that the MPV venom does not alter the usual complement response to endotoxin (8, 11) or the early hemodynamic response to endotoxin thought to be a consequence of complement activation (8) . It is concluded that, although the role of much of the coagulation sequence in the endotoxin response is not yet settled, there seems to be no evidence that disseminated fibrin clot formation plays a major role in canine endotoxin shock. ACKNOWLEDGMENTS This investigation was supported by the Minnesota Heart Association, the Minnesota Medical Foundation, Public Health Service grants 5TO1-AI-00194-09 and 5-ROl-AI-10784-02 from the National Institute of Allergy and Infectious Diseases, the Leukemia Research Foundation, and the American Heart Association.
